After Brexit: new directions for clinical trials

A new regime for clinical trials in Europe is coming into force in 2018. However, there are uncertainties about what clinical trials legislation will apply in the UK once it leaves the EU. This article is a brief summary of the changes that will come into force for businesses based in Europe and for global businesses running clinical trials in Europe, and the potential impact of Brexit.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

What 2020 means for the life sciences

15 December 2020 Between Brexit and COVID-19, 2020 has had seismic implications for the life sciences industries. Sally Shorthose and Rumana Khanom of Bird & Bird report.

Big Pharma

EMA voices ‘serious concerns’ over MA holders’ Brexit preparedness

11 July 2018 The European Medicines Agency has expressed concerns about how prepared medical marketing authorisation holders are for when the UK leaves the EU.

Big Pharma

Life sciences industry calls for Brexit transition period

29 November 2017 The EU and UK must make progress in Brexit negotiations “as soon as possible”, according to the associations that represent the European and British life sciences industry.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

GSK escalates mRNA COVID-19 vaccine dispute

The flaw that landed Sanofi a win in the rare disease space

UK firm expands in Germany with more litigation hires

After Brexit: new directions for clinical trials

More on this story

Editor's picks

Editor's picks

More features